2017/3/3

讓腫瘤餓個短暫幾天:禁食可以加強對抗癌症治療

陳駿逸醫師
科學家認為,進行拯救生命的癌症化療時合併禁食治療的患者,會有更少的化療副作用。
但是,在分析先前的研究時,對於確定禁食是否有助於戰勝癌症,以及有多少病人可以受益,大規模的研究是至關重要的。
澳大利亞布里斯班昆士蘭大學的著名醫學科學研究員Veronique Chachay博士說:“禁食肯定適用於部分癌症患者,但並不是所有人。”
荷蘭萊頓大學醫學中心的Hanno Pijl博士的研究團隊在BMC癌症雜誌上發表了驚人的研究結果:
“短期禁食可以保護健康細胞免受化療的副作用,使癌細胞更容易受到傷害。”



Starving Tumors: Fasting Boosts Cancer-Fighting Therapies
By Chris Pritchard 


Life-saving cancer-fighting chemotherapy works better with fewer side-effects in patients who combine treatment with fasting, medical scientists believe.
But, in analyzing pilot studies, they caution larger-scale research is vital to determine just how fasting helps combat cancer and how many patients can be helped.
“Fasting certainly works for some cancer patients — but not for all,” says Dr. Veronique Chachay, a prominent medical science researcher at Australia’s Brisbane-based Queensland University.
She tells Newsmax Health many scientific studies on the topic have been promising.
Among these studies is one by a team at The Netherlands’ Leiden University Medical Centre. It was led by a professor there who is one of that European nation’s leading medical researchers, Dr. Hanno Pijl.
Pijl’s team’s published its research in a in a peer-reviewed journal, BMC Cancer - with this startling conclusion: Evidence indicates “short-term fasting protects healthy cells against side-effects of chemotherapy and makes cancer cells more vulnerable to it.”
Chachay explains that cancerous cells are fueled by glucose — a type of sugar — that helps drive their energy metabolism, rapid growth, and resistance to chemotherapy.
“Under low blood-glucose conditions, cancer cells are in effect being starved, becoming more vulnerable to chemotherapy,” Chachay notes. “Over the past two decades, research in animals has shown restricting calories — with alternating periods of fasting and feeding — promotes protection mechanisms for healthy cells while increasing white blood cells that kill cancer cells, she continues.
“Further animal studies and early trials in humans confirmed short-term fasting prior to, and after, chemotherapy treatment reduced side-effects. It also protected healthy cells from the toxicity of the (chemotherapy) drug while killing cancerous ones.
Chachay says cancerous cells’ propensity to “thrive on glucose” was first demonstrated in the 1950s by a German physiologist named Dr. Otto Warburg.
“He also showed they (cancerous cells) were unable to use fatty acids efficiently for energy or at all,” Chachay notes.
“This idea of cancer being a disease reliant on rapid glucose metabolism has reemerged recently.”
In the Dutch study, short-term fasting was shown to be safe and well-tolerated.
Breast cancer patients received their normal chemotherapy drugs after 24 hours’ fasting during which they were allowed only water, tea or coffee.
“Patients who fasted did considerably better than those in a control group who didn’t fast,” says Chachay

No limits were placed on the amount of water, hot tea or coffee (without cream or sugar) patients could consume.
Chachay notes another animal study suggests restrict diets may help combat neuroblastoma — a common childhood where cancer cells congregate in nerve tissue of adrenal glands, chest, neck, or spinal cord. Neuroblastoma is ranked the third most common childhood cancer after leukemia and cancer of the central nervous system.
Chemotherapy generally involves breaks between courses of cancer-fighting medication. Patients in the Dutch study had 24-hour fasts before and after these.
The Leiden researchers, who confined themselves to breast cancer, noticed long-term fasting reduces “spontaneous cancer incidence and delays progression of tumors in animal tests.”
But, they added: “Chronic calorie restriction is not practical for clinical use since it causes unacceptable weight loss in cancer patients. However, brief periods of fasting may be feasible in patients and . . . were shown to slow cancer growth at least as effectively as chronic calorie restriction without compromising body weight.”
According to Chachay, other studies have shown short-term fasting makes chemotherapy more effective and lessens side-effects in some, but not all, other types of cancer. Among these are brain cancers.
She adds that further research is needed “involving more people and a greater variety of cancers. However, there’s already strong evidence that short-term fasting helps chemotherapy do its job and is also very effective in reducing side effects.”
As Chachay points out, side effects are sometimes so severe that patients abandon potentially lifesaving treatment.
“The aim of ongoing research is two-fold: improving the effectiveness of chemotherapy and reducing the level of side effects,” she says. “The outlook is very promising.”

2017/3/1

睡眠呼吸中止症讓肺癌致死率更高

已經有研究報告指出,睡眠呼吸中止症會讓肺癌患者的病況進行得更快、更嚴重,死亡率更高,一個由芝加哥大學及巴塞隆拿大學共同做的研究且發表在胸腔期刊(Chest)指出,有呼吸中止症的肺癌患者,在不斷間歇性的缺氧的狀況,細胞會分泌對癌細胞的增生且甚至流動,有推進的外泌體 (exosome: 攜帶有核酸與蛋白質等生物分子,扮演著細胞間重要的訊息傳遞角色,直徑約20-120 nm膜狀小囊泡),造就了腫瘤快速成長或轉移而讓肺癌變得更可怕。

估計在肥胖及超過60歲族群中,有超過20%有睡眠呼吸中止症,但當今醫療對睡眠呼吸中止症的篩檢及治療不普及,但各種生活環境條件惡化,且已顯現在升高的罹肺癌率,而睡眠呼吸中止症對高血壓心衰竭又已有很明確的有不良的影響的情況下。


<內容擷取自Science Daily>



2017/2/22

血液中高濃度的維他命C對癌症的治療有幫助嗎?

維他命C被嘗試用在癌症治療上,已有很長的歷史,結果不一的原因可能是因為他被應用的方法?

美國愛荷華大學放射腫瘤醫學教授Garry Buettner在2016年12月份的Redox Biology 所發表的研究報告指出,在愛荷華大學的Holden Comprehensive Cancer Center, 針對肺癌及胰臟癌的化療或放療輔以維他命C,一項美國國家衛生院補助的臨床一期試驗,結果顯示血液高濃度的維他命C是安全的,病人的耐受度是高的,也顯示這種輔助治療有機會改善化放療的效果。下一步大型的臨床實驗的目的,將是要研究這種治療是否能延長病友的壽命!

實驗將維他命C用靜脈注射,提高它在血液濃度高於一般的100至500倍 (毫摩爾程度),維他命C在血液中會快速的分解,產生的過氧化氫 (H2O2) 會破壞細胞組織及基因,正常的細胞有幾個途徑中和過氧化氫帶來的氧化壓力來保護細胞,但細胞表現的過氧化氫酶(catalase)是主要中和過氧化氫壓力的主要角色,但某些類的癌細胞,在過氧化氫酶的表現上是低的,也就讓這種癌細胞容易受到維他命C的破壞。

傳統維他命C治療方法大多是經由口服的,經過了胃腸道的代謝,血液中維他命C的濃度是提不高到足以產生足夠的過氧化氫,去破壞表現過氧化氫酶低的癌細胞,是維他命C能否對某些類的癌細胞產生破壞,重要的關鍵!

(內容擷取自美國愛荷華大學Iowa Now)
內容來源網址:https://medicine.uiowa.edu/content/why-high-dose-vitamin-c-kills-cancer-cells

2017/2/14

癌症全面性治療模式

在有效的改善心理及基本生理功能、提升自體免疫功能的情況下,讓癌症的治療,充分的發揮它可能的療效!

治病也要治人
一個良好的醫病關係,應該能協助病友與家屬:
  • 分析人際與環境關係,
  • 在建立了互信的醫病關係,對病友及病情有的深度了解的基礎上,「在醫療常規的檢查外」,輔以
  • 依自然醫療及能量醫療法則的檢測、
  • 完整的評估病友的整體身心狀況、
  • 整合「醫院與身心並重的癌症治療專業與資源」,來提供病友
  • 「精準的標靶及放射治療、免疫治療」、
  • 及「個人化、身心並重的自然及能量療法」的
  • 「全面性癌症治療模式」的服務與輔導
  • 在有效的改善心理及基本生理功能、提升自體免疫功能的情況下,讓癌症的治療,充分的發揮它可能的療效!

2016/11/7

Atezolizumab: 晚期非小細胞肺癌的PD-L1免疫檢查點抑制劑

【文: 中西整合癌症醫療諮詢/癌疲憊特別門診醫師 陳駿逸】

2016 年 10 月 18 日新的肺癌免疫治療藥物 TECENTRIQ® (atezolizumab)通過美國FDA 核准。TECENTRIQ®乃運用免疫系統的重新活化來抑制癌細胞生長,適用於轉移性非小細胞肺癌且使用化療或標靶治療無效的患者。

TECENTRIQ 在癌症免疫療法中屬於免疫檢查點抑制劑的一種,本身是一種單株抗體,透過與癌細胞和腫瘤內浸潤淋巴球細胞表面的免疫檢查點蛋白質 PD-L1 結合,進而阻斷 PD-1 和 B7.1 受體的交互作用,打擊癌細胞生長。目前該藥物主要用於轉移性非小細胞肺癌、而且已經接受含鉑之化療藥物但無效,以及 若有EGFR 或 ALK 基因異常且使用相對應標靶治療病情仍不見改善者。

TECENTRIQ 是第一個、也是目前唯一核准的PD-L1癌症免疫治療藥物,針對癌細胞和腫瘤內浸潤淋巴球細胞表面的免疫檢查點的PD-L1 蛋白進行阻斷作用。且無論患者的 PD-L1之水平表現如何,TECENTRIQ都能發揮作用,效果也比第二線之標準化療更好。

根據目前全球最大TECENTRIQ的第三期臨床試驗OAK,其研究結果顯示使用 TECENTRIQ 的患者平均存活時間為13.8個月,相較於使用第二線之標準化療 Docetaxel的患者多了 4.2個月的時間。

過去 15 年來,晚期非小細胞肺癌的存活率一直不斷提升,而TECENTRIQ 的核准對非小細胞肺癌病患來說是非常重要的突破,因為它提供了晚期非小細胞肺癌治療的一項新選擇。

由於 TECENTRIQ 是透過抑制 PD-L1 的表現,來活化體內的T細胞來對抗癌細胞,因此TECENTRIQ也可能導致正常細胞受損。常見的副作用有疲憊、食欲不振、呼吸短促、噁心及便秘等症狀,但也可能引發較嚴重的肺炎、肝炎、內分泌失調、神經及眼部相關疾病等。


更多癌症免疫治療新進展資訊,請連接
http://www.cancerinfotw.org/index.php/e-e-learning/2015-09-13-10-21-48/418-2016-02-27-18-42-09
陳駿逸醫師談"從傳統免疫思維談當代最夯的癌症免疫治療"


癌症不是絕症! 把握癌症早期及全面篩檢、整合醫院及診所的癌症治療專業與資源,以精準的標靶及放射治療、免疫治療,結合個人化、身心並重的的自然及能量療法的「全面性癌症治療模式」,實現整體性癌症治療的效果!